NCT05685602 2026-03-19
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
14 trialsNCT06607185 2026-03-13
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT07444541 2026-03-03
ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Anova Innovation Limited
Phase 1/2 Not yet recruiting
NCT04233866 2026-03-02
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06998940 2026-02-20
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT04115163 2026-02-11
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07383922 2026-02-04
A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Not yet recruiting
NCT06958328 2026-02-02
LAP100
NRG Oncology
Phase 3 Recruiting
NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT05026905 2026-01-20
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Active not recruiting
NCT04643405 2026-01-08
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Ascentage Pharma Group Inc.
Phase 1/2 Terminated
NCT06115499 2026-01-07
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Phase 2/3 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT07226856 2025-12-22
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
Phase 2 Recruiting